AR030727A1 - Sales de monoamina y diamina organica, sales de monoaminoacido y diaminoacido, y sales de ester de monoaminoacido y diaminoacido de precursor de fosfato de combretastatina a-4 - Google Patents

Sales de monoamina y diamina organica, sales de monoaminoacido y diaminoacido, y sales de ester de monoaminoacido y diaminoacido de precursor de fosfato de combretastatina a-4

Info

Publication number
AR030727A1
AR030727A1 ARP010104346A ARP010104346A AR030727A1 AR 030727 A1 AR030727 A1 AR 030727A1 AR P010104346 A ARP010104346 A AR P010104346A AR P010104346 A ARP010104346 A AR P010104346A AR 030727 A1 AR030727 A1 AR 030727A1
Authority
AR
Argentina
Prior art keywords
salts
monoamino acid
combretastatin
nitrogen atoms
diaminoatiz
Prior art date
Application number
ARP010104346A
Other languages
English (en)
Spanish (es)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR030727A1 publication Critical patent/AR030727A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/12Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP010104346A 2000-09-14 2001-09-13 Sales de monoamina y diamina organica, sales de monoaminoacido y diaminoacido, y sales de ester de monoaminoacido y diaminoacido de precursor de fosfato de combretastatina a-4 AR030727A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23256800P 2000-09-14 2000-09-14
US25192100P 2000-12-07 2000-12-07

Publications (1)

Publication Number Publication Date
AR030727A1 true AR030727A1 (es) 2003-09-03

Family

ID=26926130

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104346A AR030727A1 (es) 2000-09-14 2001-09-13 Sales de monoamina y diamina organica, sales de monoaminoacido y diaminoacido, y sales de ester de monoaminoacido y diaminoacido de precursor de fosfato de combretastatina a-4

Country Status (26)

Country Link
US (2) US6670344B2 (https=)
EP (1) EP1320534B1 (https=)
JP (2) JP4149804B2 (https=)
KR (1) KR100858464B1 (https=)
CN (1) CN100338077C (https=)
AR (1) AR030727A1 (https=)
AT (1) ATE293630T1 (https=)
AU (2) AU785183B2 (https=)
BR (1) BRPI0107210B1 (https=)
CA (1) CA2422359C (https=)
DE (1) DE60110249T2 (https=)
EE (1) EE200200249A (https=)
ES (1) ES2241872T3 (https=)
HK (1) HK1052356B (https=)
HU (1) HU229055B1 (https=)
IL (3) IL149601A0 (https=)
MX (1) MXPA03002209A (https=)
NO (1) NO329973B1 (https=)
NZ (1) NZ524926A (https=)
PE (1) PE20020445A1 (https=)
PT (1) PT1320534E (https=)
RS (1) RS50309B (https=)
SK (1) SK287117B6 (https=)
TW (1) TWI250163B (https=)
UY (1) UY26935A1 (https=)
WO (1) WO2002022626A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019944D0 (en) * 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US20050153939A1 (en) * 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
WO2002086869A1 (en) * 2001-04-19 2002-10-31 Sony Corporation Digital recording/reproducing apparatus
JP2004536847A (ja) * 2001-07-13 2004-12-09 オキシジーン, インコーポレイテッド 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
CN100365000C (zh) * 2003-09-18 2008-01-30 雍智全 Combretastatin A-4磷酰胆碱类前体药物以及其合成与应用
AR046970A1 (es) 2003-12-23 2006-01-04 Schering Plough Ltd Esteres de fosfato de florfenicol
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
ES2551086T3 (es) 2005-06-14 2015-11-16 Baylor University Análogos de combretastatina con actividad de unión a tubulina
CN1907989B (zh) * 2005-08-02 2011-08-17 浙江天皇药业有限公司 毛兰素盐及其制备方法和包含其的药物组合物
JP2009521424A (ja) * 2005-12-19 2009-06-04 メチルジーン インコーポレイテッド 抗真菌剤の活性を増強するためのヒストンデアセチラーゼ阻害剤
KR101784001B1 (ko) 2006-04-04 2017-10-23 케이지 액퀴지션 엘엘씨 항혈소판제와 산 억제제를 포함하는 경구 투여용 약학 조성물
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
MX2009006542A (es) 2006-12-19 2009-06-30 Methylgene Inc Inhibidores de histona desacetilasa y sus profarmacos.
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US20090012325A1 (en) * 2007-02-22 2009-01-08 Ajith Manage Methods for preparing phosphoric acids of combrestastatin and derivatives thereof
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
DE602008005316D1 (de) * 2007-06-22 2011-04-14 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
MX2009013499A (es) * 2007-06-22 2010-01-18 Bristol Myers Squibb Co Composiciones comprimidas que contienen atazanavir.
JP2010530892A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
CN101778624A (zh) * 2007-06-22 2010-07-14 百时美施贵宝公司 含有阿扎那韦的压片组合物
WO2009067706A1 (en) 2007-11-21 2009-05-28 Oxigene, Inc. Method for treating hematopoietic neoplasms
CN102757338B (zh) * 2012-02-29 2015-02-25 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸氨基酸乙酯盐、制备方法及其用途
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP2972394A4 (en) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90-DESIGNING AND THERAPY
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018144910A1 (en) 2017-02-02 2018-08-09 Bioventures, Llc Methods of protecting against neurodegeneration
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2025250885A1 (en) * 2024-05-31 2025-12-04 Oncotelic, Inc. In situ tumor-infiltrating lymphocyte therapeutics for cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
DE3438386A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Phosphorsaeurevinylbenzylester, ihre herstellung und verwendung
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
DE19506885A1 (de) 1995-02-17 1996-08-22 Schering Ag Neue Borneolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
WO1999035159A1 (en) * 1998-01-08 1999-07-15 Brigham & Women's Hospital, Inc. Lymphoma/leukemia oncogene, oncoprotein and methods of use
EP1045853B1 (en) * 1998-01-09 2010-08-04 ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY Synthesis of combretastatin a-4 prodrugs
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
GB0019944D0 (en) 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
SK287117B6 (sk) 2009-12-07
SK6722002A3 (en) 2002-11-06
WO2002022626A1 (en) 2002-03-21
JP4149804B2 (ja) 2008-09-17
CA2422359C (en) 2008-12-23
US20040054212A1 (en) 2004-03-18
KR20020063187A (ko) 2002-08-01
PE20020445A1 (es) 2002-05-18
HUP0204423A3 (en) 2005-02-28
IL176088A0 (en) 2006-10-05
NO20022270D0 (no) 2002-05-13
AU785183B2 (en) 2006-10-19
NO329973B1 (no) 2011-01-31
AU2007200218A1 (en) 2007-02-08
WO2002022626A8 (en) 2002-04-18
DE60110249D1 (de) 2005-05-25
CA2422359A1 (en) 2002-03-21
CN1392876A (zh) 2003-01-22
JP2004509128A (ja) 2004-03-25
HK1052356B (zh) 2008-06-27
RS50309B (sr) 2009-09-08
ATE293630T1 (de) 2005-05-15
EP1320534B1 (en) 2005-04-20
KR100858464B1 (ko) 2008-09-16
UY26935A1 (es) 2002-04-26
US6670344B2 (en) 2003-12-30
ES2241872T3 (es) 2005-11-01
HUP0204423A2 (en) 2003-05-28
IL149601A (en) 2007-06-17
US20020072507A1 (en) 2002-06-13
TWI250163B (en) 2006-03-01
NO20022270L (no) 2002-07-01
MXPA03002209A (es) 2004-03-02
NZ524926A (en) 2004-10-29
HU229055B1 (hu) 2013-07-29
IL149601A0 (en) 2002-11-10
BRPI0107210B1 (pt) 2017-09-26
CN100338077C (zh) 2007-09-19
DE60110249T2 (de) 2006-03-02
AU9077101A (en) 2002-03-26
BR0107210A (pt) 2003-02-25
HK1052356A1 (en) 2003-09-11
EE200200249A (et) 2003-06-16
JP2008195740A (ja) 2008-08-28
PT1320534E (pt) 2005-08-31
YU34802A (sh) 2005-07-19
US6855702B2 (en) 2005-02-15
EP1320534A1 (en) 2003-06-25

Similar Documents

Publication Publication Date Title
AR030727A1 (es) Sales de monoamina y diamina organica, sales de monoaminoacido y diaminoacido, y sales de ester de monoaminoacido y diaminoacido de precursor de fosfato de combretastatina a-4
CR9587A (es) Derivados de piridazina
DOP2002000392A (es) Sales tartrato de 5,8,14 triazatetraciclo [10.3.1.024 0.4.9] hexadeca-2 (11), 3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
MX2009007474A (es) Proceso para la preparacion de acido 5-bifenil-4-amino-2-metil pentanoico.
AR058293A1 (es) Sales profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]pirimidin-5-carbonil)-2-metoxi-fenil]-3-(2,4-dicloro-fenil)-urea
PA8557001A1 (es) Nuevos derivados de pirrolidina
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
NZ600028A (en) Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis
AR009911A1 (es) Derivados de acido benzazepinona-n-acetico, sustituidos con acidos fosfonicos, asi como procedimientos para su preparacion y medicamentos que contienen estos compuestos
AR079404A1 (es) Antagonista dp2 y composicion farmaceutica, uso y proceso de preparacion
AR040010A1 (es) Derivados de (imidazol-1-il-metil)-piridazina
AR024462A1 (es) Tabletas farmaceuticas
AR058163A1 (es) Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona
AR047382A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
DOP2010000283A (es) Inhibidores de desacetilasas b a base de hidroxamato
CY1106335T1 (el) Υποκατεστημενα παραγωγα 4-φαινυλ-4[1η-ιμιδαζολ-2-υλ]-πιπepιδινης για τη μειωση της ισχαιμικης βλαβης
MA31094B1 (fr) Utilisation de dérivés de pyranone-acide substituée pour le traitement du syndrome métabolique
CO6230988A2 (es) Jarabes antihistaminicos estables al almacenamiento sin azucar
AR026338A1 (es) Dihidrotiazoles policiclicos, provistos en posicion 2 de radicales alquilo sustituidos, procedimiento para su preparacion y su utilizacion comomedicamentos
AR040763A1 (es) Profarmacos de la (n-2- piridil-n-2- hidroxicarbonil-etil) - amida del acido 1- metil-2-(4-amidinofenilaminometil)-- benzimidazol-5-il-carboxilico, su preparacion y su utilizacion como medicamentos
ECSP10010421A (es) Procedimiento de preparación de combretastatina
MX2009011449A (es) Agente terapeutico o profilactico para disquinesia.
AR069249A1 (es) Derivado de indazol, activo en el dolor neuropatico
AR039283A1 (es) Derivados de benzopirano sustituidos con aminas secundarias que incluyen tetrazol, metodo para su preparacion y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure